Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848627 · ClinicalTrials.gov registry record
Screening for Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- 197
- Enrollment target
- 3
- Study locations
NCT00848627: Completed study of Bladder Cancer, sponsored by Baylor College of Medicine.
NCT00848627 is a study of Bladder Cancer that has completed, run by Baylor College of Medicine. The registered enrollment target is 197 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00848627, a study of Bladder Cancer, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- 197 participants
- Enrollment target
- 3
- Study locations
Study Summary
In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine the cause of hematuria and follow-up will continue for 2 years after completion of the study.
Conditions Studied
Interventions
- OTHER Specimen and questionnaires only
Study Locations (3)
New York
- University of Rochester Medical Center - Rochester
Texas
- M.D. Anderson Cancer Center - Houston
Quebec
- Laval University - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-02 |
What the finished NCT00848627 record still lists
NCT00848627 is an observational study that tracks outcomes without assigning an intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Specimen and questionnaires only is the first listed.
NCT00848627 reports a single indexed study location in New York, Texas, Quebec.
Frequently Asked Questions
What is clinical trial NCT00848627 about?
NCT00848627 is a clinical study titled "Screening for Bladder Cancer". In the study proposed, up to 1,500 men age 60 and over with strong smoking histories will test their urine for the presence of blood daily for two 10-day testing periods with the Ames Hemastix. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine th...
What is the current status of trial NCT00848627?
This trial is currently completed. The enrollment target is 197 participants. The study started on 2007-03. Estimated completion is 2012-02.
What conditions does trial NCT00848627 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00848627?
The interventions under investigation include: Specimen and questionnaires only (OTHER).
Who is sponsoring clinical trial NCT00848627?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848627 being conducted?
This trial has 3 study locations across New York, Texas, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00848627's enrollment target sits among peer trials
197 57th of 175 higher than 119 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04219254 · 197 participants · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia